

Please type a plus sign (+) inside this box → 

Approved for use through 10/31/2002. OMB 0651-0032  
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.83 (a))

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1  Fee Transmittal Form (e.g., PTO/SB/17)  
 (Submit an original and a duplicate for fee processing)

2  Applicant claims small entity status.  
 See 37 CFR 1.27.

3  Specification [Total Pages  
 (preferred arrangement set forth below) 124 ]

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

4  Drawing(s)/35 U.S.C.113) [Total  
 Sheets] 8  
 5. Oath or Declaration [Total  
 Pages] 2

a.  Unexecuted (original or copy)

b.  Copy from a prior application (37 CFR 1.63(d))  
 (for continuation/divisional with Box 17 completed)

6.  DELETION OF INVENTOR(S)  
 Signed statement attached deleting inventor(s)  
 named in the prior application, see 37 CFR  
 1.63(d)(2) and 1.33(b).

6.  Application Data Sheet. See 37 CFR 1.76

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_  
 Prior application information: Examiner: \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

Attorney Docket No.	LEX-0126-USA
First Inventor	Glenn Friedrich et al.
Title	Novel Mutated Mammalian Cells and Animals
Express Mail Label No.	EL 747066882 US

Assistant Commissioner for Patents  
 Box Patent Application  
 Washington, DC 20231

7.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8 Nucleotide and/or Amino Acid Sequence Submission  
 (if applicable, all necessary)

a.  Computer Readable Form (CRF)

b. Specification Sequence Listing on:  
 i.  CD-ROM or CD-R (2 copies); or  
 ii.  paper

c.  Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9.  Assignment Papers (cover sheet & document(s))

10.  37 CFR 3.73(b) Statement (when there is an assignee)  Attorney of record

11.  English Translation Document (if applicable)

12.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

13.  Preliminary Amendment

14.  Return Receipt Postcard (MPEP 603)  
 (Should be specifically itemized)

15.  Certified Copy of Priority Document(s)  
 (if foreign priority is claimed)

16.  Other: \_\_\_\_\_

18. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label

 Correspondence address below

Name	Lance K. Ishimoto			
Address	4000 Research Forest Drive			
City	The Woodlands	State	TX	Zip
Country	Telephone		(281) 863-3333	Fax
Name (Print/Type)	Lance K. Ishimoto		Registration No. (Attorney/Agent)	41866
Signature			Date January 31, 2001	

Burden Hour Statement: This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

<b>REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)</b>		First Named Inventor	Glenn Friedrich et al.
Title	Novel Mutated Mammalian Cells and		
Atty Docket Number		LEX-0126-USA	

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

January 31, 2001  
Date



Signature

Lance K. Ishimoto  
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37.1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.